Drug Profile
GSK 2302032A
Alternative Names: GSK2302032A; PRAME Antigen Specific Cancer Immunotherapeutic - NSCLC; PRAME-ASCI-Non-small cell lung cancerLatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 01 Aug 2016 GSK completes a phase-II clinical trial in Non-small cell lung cancer (Adjuvant therapy) Estonia, France, Germany, Japan, South Korea, Poland, Russia, United Kingdom and USA (NCT01853878)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in France (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in Germany (IM, Injection)